247 related articles for article (PubMed ID: 30958398)
21. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
Kaplan AL; Lenis AT; Shah A; Rajfer J; Hu JC
J Sex Med; 2015 Feb; 12(2):374-80. PubMed ID: 25496237
[TBL] [Abstract][Full Text] [Related]
22. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
Kollmeier MA; Zelefsky MJ
Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
[TBL] [Abstract][Full Text] [Related]
23. Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer.
Kim JW
Investig Clin Urol; 2020 May; 61(3):242-249. PubMed ID: 32377599
[TBL] [Abstract][Full Text] [Related]
24. Androgen deficiency in older men: indications, advantages, and pitfalls of testosterone replacement therapy.
McGill JJ; Shoskes DA; Sabanegh ES
Cleve Clin J Med; 2012 Nov; 79(11):797-806. PubMed ID: 23125330
[TBL] [Abstract][Full Text] [Related]
25. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
[TBL] [Abstract][Full Text] [Related]
26. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Morgentaler A
J Urol; 2009 Mar; 181(3):972-9. PubMed ID: 19150547
[TBL] [Abstract][Full Text] [Related]
27. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
28. Androgen deficiency in the aging male: a guide to diagnosis and testosterone replacement therapy.
Raynor MC; Carson CC; Pearson MD; Nix JW
Can J Urol; 2007 Dec; 14 Suppl 1():63-8. PubMed ID: 18163948
[TBL] [Abstract][Full Text] [Related]
29. [Role of androgen in the elderly. Problems of androgen deprivation therapy].
Tsujimura A
Clin Calcium; 2013 Aug; 23(8):1185-90. PubMed ID: 23892220
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Bélanger A; Dupont A; Labrie F
J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
[TBL] [Abstract][Full Text] [Related]
31. Androgens, brain and androgen deprivation therapy in paraphilic disorders: A narrative review.
Baltodano-Calle MJ; Onton-Díaz M; Gonzales GF
Andrologia; 2022 Nov; 54(10):e14561. PubMed ID: 35995581
[TBL] [Abstract][Full Text] [Related]
32. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
[TBL] [Abstract][Full Text] [Related]
33. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
[TBL] [Abstract][Full Text] [Related]
34. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.
Kwon DH; Vashisht R; Borno HT; Aggarwal RR; Small EJ; Butte AJ; Huang FW
Ann Oncol; 2021 May; 32(5):678-679. PubMed ID: 33571636
[No Abstract] [Full Text] [Related]
35. Androgen replacement therapy in aging men.
Katz A
Nurse Pract; 2004 Oct; 29(10):58-64. PubMed ID: 15489672
[No Abstract] [Full Text] [Related]
36. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.
Gagliano-Jucá T; Travison TG; Nguyen PL; Kantoff PW; Taplin ME; Kibel AS; Manley R; Hally K; Bearup R; Beleva YM; Huang G; Edwards RR; Basaria S
J Pain Symptom Manage; 2018 Feb; 55(2):307-317.e1. PubMed ID: 28941963
[TBL] [Abstract][Full Text] [Related]
37. Anti-androgens and other hormonal therapies for prostate cancer.
Richie JP
Urology; 1999 Dec; 54(6A Suppl):15-8. PubMed ID: 10606279
[TBL] [Abstract][Full Text] [Related]
38. The role of testosterone, the androgen receptor, and hypothalamic-pituitary-gonadal axis in depression in ageing Men.
Hauger RL; Saelzler UG; Pagadala MS; Panizzon MS
Rev Endocr Metab Disord; 2022 Dec; 23(6):1259-1273. PubMed ID: 36418656
[TBL] [Abstract][Full Text] [Related]
39. The management of hot flushes for men treated with androgen deprivation therapy for prostate cancer: a survey of UK practice.
Kinnaird W; Mehta A; Guo C; Payne H; Jenkins V; Catt S
Acupunct Med; 2021 Aug; 39(4):394-395. PubMed ID: 33023298
[No Abstract] [Full Text] [Related]
40. Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.
Ishizaki F; Hara N; Takizawa I; Nishiyama T; Isahaya E; Kawasaki T; Takahashi K
Growth Horm IGF Res; 2012; 22(3-4):122-8. PubMed ID: 22579549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
